Subject category:
Strategy and General Management
Published by:
IBS Case Development Center
Length: 8 pages
Data source: Published sources
Share a link:
https://casecent.re/p/63050
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
In the year 2000, GlaxoWellcome plc and SmithklineBeecham plc merged to form GlaxoSmithkline plc (GSK). In recent years GSK has been facing challenges on many fronts: patent expiration, lack of promising drugs and ongoing lawsuits. With increasing pressure on the profit margins, GSK is revamping its strategy to sustain its leadership in the global pharmaceutical industry. The case helps in discussing how GSK is dealing with the competition it is facing from the generic drug makers and its growth strategies with respect to new drug development.
About
Abstract
In the year 2000, GlaxoWellcome plc and SmithklineBeecham plc merged to form GlaxoSmithkline plc (GSK). In recent years GSK has been facing challenges on many fronts: patent expiration, lack of promising drugs and ongoing lawsuits. With increasing pressure on the profit margins, GSK is revamping its strategy to sustain its leadership in the global pharmaceutical industry. The case helps in discussing how GSK is dealing with the competition it is facing from the generic drug makers and its growth strategies with respect to new drug development.